Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | UBE2M | P61081 | 2/20 | 0.32 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6920061 | 0.90 | ALDH1A1 (0.36) | BACE1BACE2GAAKMT2AALDH1A1 | |
| SCHEMBL8515730 | 0.89 | BACE1 (0.38) | BACE1BACE2 | |
| SCHEMBL8516042 | 0.86 | ALDH1A1 (0.36) | BACE1BACE2GAAKMT2ALMNA | |
| SCHEMBL8516035 | 0.86 | ALDH1A1 (0.36) | BACE1BACE2GAAKMT2ALMNA | |
| SCHEMBL11900491 | 0.79 | BACE1 (0.54) | BACE1BACE2 | |
| SCHEMBL6920051 | 0.79 | BACE1 (0.37) | BACE1BACE2ALDH1A1 | |
| SCHEMBL991173 | 0.78 | BACE1 (0.38) | BACE1BACE2KMT2AALDH1A1 | |
| SCHEMBL6919820 | 0.77 | ALDH1A1 (0.36) | BACE1BACE2GAAHTTALDH1A1 | |
| SCHEMBL11901104 | 0.77 | BACE1 (0.41) | BACE1BACE2 | |
| Ammonia Solution, Strong SCHEMBL8514730 | 0.76 | BACE1 (0.40) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139594-B2 | Fused aminodihydropyrimidone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20120202828-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| EP-2456771-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011009897-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD (JP) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202828-A1 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885GAA 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.